Wellington Management Group LLP Increases Stake in Annexon, Inc. $ANNX

Wellington Management Group LLP increased its holdings in Annexon, Inc. (NASDAQ:ANNX) by 32.9% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 356,480 shares of the company’s stock after purchasing an additional 88,314 shares during the period. Wellington Management Group LLP owned approximately 0.32% of Annexon worth $688,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. BNP Paribas Financial Markets purchased a new stake in shares of Annexon in the 4th quarter valued at $59,000. Forefront Analytics LLC raised its holdings in Annexon by 56.8% during the 4th quarter. Forefront Analytics LLC now owns 16,433 shares of the company’s stock valued at $84,000 after buying an additional 5,950 shares during the last quarter. Comerica Bank raised its holdings in Annexon by 22.7% during the 4th quarter. Comerica Bank now owns 23,183 shares of the company’s stock valued at $119,000 after buying an additional 4,283 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in Annexon by 345.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 24,892 shares of the company’s stock valued at $128,000 after buying an additional 19,301 shares during the last quarter. Finally, Shay Capital LLC bought a new stake in Annexon during the 4th quarter valued at $159,000.

Annexon Trading Down 2.8%

Shares of NASDAQ ANNX opened at $2.06 on Tuesday. Annexon, Inc. has a 12 month low of $1.28 and a 12 month high of $7.85. The firm has a market capitalization of $226.37 million, a PE ratio of -1.60 and a beta of 1.16. The firm has a fifty day simple moving average of $2.44 and a two-hundred day simple moving average of $2.26.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.02. On average, sell-side analysts predict that Annexon, Inc. will post -0.96 earnings per share for the current year.

Analyst Ratings Changes

ANNX has been the subject of a number of recent analyst reports. Zacks Research upgraded shares of Annexon from a “strong sell” rating to a “hold” rating in a report on Monday, August 18th. HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of Annexon in a report on Friday, August 15th. Finally, Needham & Company LLC lowered their price target on shares of Annexon from $16.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, May 13th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $12.50.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.